Clinical Report: Evolving Treatment Strategies for Noninfectious Uveitis
Overview
Recent advances in treatment options for noninfectious uveitis (NIU) include improved corticosteroid delivery systems and new immunomodulatory therapies.
Background
Noninfectious uveitis is a significant cause of vision loss, with rates of legal blindness remaining unchanged over the past three decades. The evolving treatment landscape, including local and systemic therapies, is crucial for improving patient outcomes.
Data Highlights
No numerical data available in the source material.
Key Findings
Corticosteroids remain the cornerstone of treatment for acute ocular inflammation.
The fluocinolone acetonide 0.59 mg intravitreal implant provided superior inflammation control compared to systemic therapy in the Multicenter Uveitis Steroid Treatment trial.
The fluocinolone acetonide 0.19-mg intravitreal implant (Iluvien) offers sustained corticosteroid delivery for up to 36 months.
Patients treated with the fluocinolone acetonide implant had a lower frequency of recurrence (65.5%) compared to sham treatment (97.6%).
Suprachoroidal triamcinolone acetonide (Xipere) was approved to treat uveitic macular edema, showing sustained improvement in vision.
Intravitreal triamcinolone remains a useful option for rapid local control of inflammation and macular edema.
Clinical Implications
The advancements in local corticosteroid delivery systems and the introduction of new therapies provide clinicians with more options for managing noninfectious uveitis.
Conclusion
Continued research and development are necessary to address the ongoing challenges in treating this condition.
Joseph P. Shovlin, OD, FAAO, reviewed diagnosis, management, and emerging evidence related to chronic herpetic eye disease prevention at Optometry's Meeting 2026.
